Cytokinetics is a California-based biopharmaceutical company that researches and develops muscle activators and muscle inhibitors to treat cardiovascular diseases.
Business Model:
Revenue: $148.2M
Employees: 201-500
Address: 350 Oyster Point Boulevard
City: South San Francisco
State: CA
Zip: 94080
Country: US
Cytokinetics is a California-based biopharmaceutical company that researches and develops muscle activators and muscle inhibitors to treat cardiovascular diseases.
Contact Phone:
+16506243000
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
4/29/2004
IPO Valuation:
$338M
Ticker Symbol:
CYTK
IPO Price:
$13/share
Amount Raised:
$90M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2023 | The Mended Hearts | Grant | 20k |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2003 | Series E | 1 | $40M |
Vulcan Vulcan Vulcan Vulcan |
6/2012 | Post-IPO Equity | $42.5M | 4/2011 | Post-IPO Equity | 1 | $20M |
Deerfield Deerfield Deerfield Deerfield |
7/2022 | Post-IPO Debt | $0 |
Royalty Pharma Royalty Pharma |
11/2019 | Post-IPO Equity | $120M | 2/2017 | Post-IPO Equity | $100M |
Royalty Pharma |
1/2022 | Post-IPO Equity | $50M |
Royalty Pharma |
1/2006 | Post-IPO Equity | 2 | $33M |
Federated Kaufmann Fund Red Abbey Venture Partners Federated Kaufmann Fund Red Abbey Venture Partners |
7/2020 | Post-IPO Equity | $201.3M | 7/2021 | Post-IPO Equity | $316.3M | 2/2014 | Post-IPO Equity | $37.4M | 7/2022 | Post-IPO Debt | 1 | $450M |
Royalty Pharma Royalty Pharma |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|